Overview
The goal of this clinical trial is to assess Honey in orabase (1:1) for treating patients with OLP and improving their quality of life:
The research question aims to answer:
Does honey in orabase (1:1) improve or reduce OLP symptoms compared to the standardized treatment by triamcinolone acetonide 0.1% drug and improve the patient's quality of life?
Participants will:
Take drug ABC or a placebo every day for 4 months Visit the clinic once every 2 weeks for checkups and tests Keep a diary of their symptoms and the number of times they use a rescue inhaler
Description
The study comprised 56 patients diagnosed with Oral Lichen Planus, who were randomly selected according to inclusion and exclusion criteria. The subjects were between 35 and 60 years old, capable of complying with the study procedure, and provided informed consent. Exclusion criteria encompassed those with alternative oral mucosal illnesses, systemic problems influencing OLP or wound healing, allergies or sensitivities to honey or triamcinolone, or those receiving systemic corticosteroids or immunosuppressive drugs. Individuals who were pregnant or lactating, as well as those unable to provide informed written consent, were excluded.
Eligibility
Inclusion Criteria:
- Patients with a clinical diagnosis of oral lichen planus
- Symptomatic OLP lesions (erosive/atrophic)
- Participants are between 35 and 60 years old, who are able to adhere to the study protocol, and sign informed consent.
Exclusion Criteria:
- Patients with other oral mucosal disorders, or systemic conditions influencing OLP or wound healing, allergies or hypersensitivity to honey or triamcinolone
- Patients who administer systemic corticosteroids or immunosuppressive agents.
- Pregnancy or lactation
- Inability to comprehend or adhere to study directives
- Patients who are not able to sign an informed written consent